Zenyaku Kogyo Co. Ltd. has identified myosin light chain kinase family member 4 (MYLK4; SGK085) inhibitors reported to be useful for the treatment of arteriosclerosis, inflammatory bowel disease, osteosarcoma, glaucoma, ocular hypertension, dry eye, uveitis and age-related macular degeneration, among others.